• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).

作者信息

Jensen M, Winkler U, Manzke O, Diehl V, Engert A

机构信息

Department I for Internal Medicine, University of Cologne, Köln, Germany.

出版信息

Ann Hematol. 1998 Jul-Aug;77(1-2):89-91. doi: 10.1007/s002770050419.

DOI:10.1007/s002770050419
PMID:9760161
Abstract

In this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome after administration of the human anti-CD20 antibody IDEC-C2B8 (RITUXIMAB) in standard dose of 375 mg/m2. IDEC-C2B8 has been demonstrated to have only mild and tolerable side effects in patients with follicular lymphoma. In these trials patients with lymphocytosis >5000/microl were excluded. Physicians must be aware of this hitherto unreported phenomenon in patients with high CD20-positive blood counts.

摘要

相似文献

1
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
Ann Hematol. 1998 Jul-Aug;77(1-2):89-91. doi: 10.1007/s002770050419.
2
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.嵌合抗CD20单克隆抗体（IDEC-C2B8，利妥昔单抗）用于复发B细胞淋巴瘤的可行性及药代动力学研究。IDEC-C2B8研究组
Ann Oncol. 1998 May;9(5):527-34. doi: 10.1023/a:1008265313133.
3
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment.
Blood. 2001 Sep 15;98(6):1991-2. doi: 10.1182/blood.v98.6.1991.
4
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).B细胞慢性淋巴细胞白血病且淋巴细胞计数高的患者在接受抗CD20单克隆抗体（利妥昔单抗，IDEC-C2B8）治疗后发生的细胞因子释放综合征
Blood. 1999 Oct 1;94(7):2217-24.
5
Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.利妥昔单抗用于淋巴增殖性疾病（高度恶性非霍奇金淋巴瘤和慢性淋巴细胞白血病）治疗后发生的肿瘤溶解综合征
Am J Hematol. 1999 Dec;62(4):247-50. doi: 10.1002/(sici)1096-8652(199912)62:4<247::aid-ajh9>3.0.co;2-t.
6
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.利妥昔单抗（IDEC-C2B8）抗CD20单克隆抗体疗法用于复发性低度非霍奇金淋巴瘤患者。
Blood. 1997 Sep 15;90(6):2188-95.
7
Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.用嵌合抗CD20单克隆抗体（IDEC-C2B8，利妥昔单抗）成功治疗一名复发套细胞淋巴瘤患者，该患者产生了人抗嵌合抗体。
Int J Hematol. 2001 Jul;74(1):70-5. doi: 10.1007/BF02982552.
8
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.抗CD20抗体（IDEC-C2B8，利妥昔单抗）在体外增强细胞毒性药物对肿瘤淋巴细胞的疗效：细胞因子、补体和半胱天冬酶的作用
Haematologica. 2002 Jan;87(1):33-43.
9
Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.难治性或复发性B细胞幼淋巴细胞白血病和B细胞慢性淋巴细胞白血病患者的CD20表达水平及利妥昔单抗治疗效果
Leuk Lymphoma. 2002 Jan;43(1):149-51. doi: 10.1080/10428190210178.
10
Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.通过抗CD20单克隆抗体利妥昔单抗治疗选择B细胞慢性淋巴细胞白血病细胞变体。
Exp Hematol. 2001 Dec;29(12):1410-6. doi: 10.1016/s0301-472x(01)00753-6.

引用本文的文献

1
Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System.用于慢性淋巴细胞白血病的CD20单克隆抗体所致肿瘤溶解综合征：来自美国食品药品监督管理局不良事件报告系统的信号
Clin Drug Investig. 2023 Oct;43(10):773-783. doi: 10.1007/s40261-023-01308-0. Epub 2023 Sep 27.
2
Tumor lysis syndrome in childhood malignancies.儿童恶性肿瘤中的肿瘤溶解综合征
Drugs Context. 2020 Feb 25;9. doi: 10.7573/dic.2019-8-2. eCollection 2020.
3
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia: A Rare Case Report from Nephrology.
慢性淋巴细胞白血病中的肿瘤溶解综合征：来自肾脏病学的一例罕见病例报告
Am J Case Rep. 2019 Nov 29;20:1776-1780. doi: 10.12659/AJCR.917211.
4
Renal involvement in chronic lymphocytic leukemia.慢性淋巴细胞白血病的肾脏受累情况。
Clin Kidney J. 2018 Oct;11(5):670-680. doi: 10.1093/ckj/sfy026. Epub 2018 Apr 11.
5
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.新型靶向药物治疗慢性淋巴细胞白血病相关肿瘤溶解综合征。
Oncologist. 2017 Nov;22(11):1283-1291. doi: 10.1634/theoncologist.2017-0055. Epub 2017 Aug 29.
6
Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.骨髓受累可预测 B 细胞淋巴瘤患者接受利妥昔单抗治疗时的输注相关反应。
Support Care Cancer. 2013 Apr;21(4):1145-52. doi: 10.1007/s00520-012-1639-9. Epub 2012 Oct 31.
7
Role of rituximab in first-line treatment of chronic lymphocytic leukemia.利妥昔单抗在慢性淋巴细胞白血病一线治疗中的作用。
Ther Clin Risk Manag. 2010 Dec 22;7:1-11. doi: 10.2147/TCRM.S5855.
8
Rituximab in the treatment of non-Hodgkin's lymphoma.利妥昔单抗治疗非霍奇金淋巴瘤
Biologics. 2008 Dec;2(4):619-33. doi: 10.2147/btt.s3235.
9
[Rituximab in treatment for neuroimmunological diseases].[利妥昔单抗在神经免疫性疾病治疗中的应用]
Nervenarzt. 2009 Feb;80(2):155-6, 158-60, 162-5. doi: 10.1007/s00115-008-2663-3.
10
Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.利妥昔单抗-环磷酰胺、阿霉素、长春新碱和泼尼松（Rituximab-CHOP）方案诱发了播散性结外边缘区B细胞淋巴瘤患者的间质性肺炎。
Yonsei Med J. 2008 Feb 29;49(1):155-8. doi: 10.3349/ymj.2008.49.1.155.